Increased immunogen valency improves the maturation of vaccine-elicited HIV-1 VRC01-like antibodies
PLOS Pathogens · 2025
DOI: 10.1371/journal.ppat.1013039 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2025. Verfasst von Parul Agrawal und 11 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America. Hauptthemen laut MEDLINE: AIDS Vaccines, HIV Antibodies, HIV-1, Antibodies, Neutralizing. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute for Health, National Institute of Health.
Abstract (Originalsprache)
Antibodies belonging to the VRC01-class display broad and potent neutralizing activities and have been isolated from several people living with HIV (PLWH). A member of that class, monoclonal antibody VRC01, was shown to reduce HIV-acquisition in two phase 2b efficacy trials. VRC01-class antibodies are therefore expected to be one component of an effective HIV-1 vaccine elicited response. In contrast to the VRC01-class antibodies that are highly mutated, their unmutated forms do not engage HIV-1 envelope (Env) and do not display neutralizing activities. Hence, specifically modified Env-derived proteins have been designed to engage the unmutated forms of VRC01-class antibodies, and to activate the corresponding naïve B cells. Selected heterologous Env must then be used as boost immunogens to guide the proper maturation of these elicited VRC01-class antibodies. Here we examined whether and how the valency of the prime and boost immunogens influences VRC01-class antibody-maturation. Our findings indicate that, indeed the valency of the immunogen affects the maturation of elicited antibody responses by preferentially selecting VRC01-like antibodies that have accumulated somatic mutations present in broadly neutralizing VRC01-class antibodies isolated from PLWH. As a result, antibodies isolated from animals immunized with the higher valency immunogens display broader Env cross-binding properties and improved neutralizing potentials than those isolated from animals immunized with the lower valency immunogens. Our results are relevant to current and upcoming phase 1 clinical trials that evaluate the ability of novel immunogens aiming to elicit cross-reactive VRC01-class antibody responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
- Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
- Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
- Division of Surgical Sciences, Duke University Medical Center, Durham, North Carolina, United States of America.
- Howard Hughes Medical Institute, Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, Washington, United States of America.
- Department of Genome Sciences, University of Washington, Seattle, Washington, United States of America.
ORCID-Profile: Leonidas Stamatatos
Förderung
- NIAID NIH HHS
- National Institute for Health
- National Institute of Health
- Howard Hughes Medical Institute
Zitieren
APA
Agrawal, P., Khechaduri, A., Salladay, K. R., MacCamy, A., Ralph, D. K., Riker, A., Stuart, A. B., Siddaramaiah, L. K., Shen, X., Matsen, F. A., Montefiori, D., & Stamatatos, L. (2025). Increased immunogen valency improves the maturation of vaccine-elicited HIV-1 VRC01-like antibodies. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1013039
Vancouver
Agrawal P, Khechaduri A, Salladay KR, MacCamy A, Ralph DK, Riker A, et al. Increased immunogen valency improves the maturation of vaccine-elicited HIV-1 VRC01-like antibodies. PLOS Pathogens. 2025. doi:10.1371/journal.ppat.1013039
BibTeX
@article{Agrawal2025,
author = {Agrawal, Parul and Khechaduri, Arineh and Salladay, Kelsey R and MacCamy, Anna and Ralph, Duncan K and Riker, Andrew and Stuart, Andrew B and Siddaramaiah, Latha Kallur and Shen, Xiaoying and Matsen, Frederick A and Montefiori, David and Stamatatos, Leonidas},
title = {Increased immunogen valency improves the maturation of vaccine-elicited HIV-1 VRC01-like antibodies},
journal = {PLOS Pathogens},
year = {2025},
doi = {10.1371/journal.ppat.1013039}
}
EUVIMED